The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
J-TAIL-2: A prospective, observational study of atezolizumab (atezo) combined with carboplatin and etoposide (CE) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) in Japan.
 
Ryota Saito
No Relationships to Disclose
 
Makoto Nishio
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Eisai; Janssen; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kadoaki Ohashi
No Relationships to Disclose
 
Atsushi Osoegawa
Honoraria - AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma
Speakers' Bureau - AstraZeneca; Chugai Pharma; MSD Oncology; Ono Pharmaceutical
 
Eiki Kikuchi
No Relationships to Disclose
 
Hideharu Kimura
No Relationships to Disclose
 
Yasushi Goto
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/UCB Japan; Guardant Health AMEA; Janssen; Lilly Japan; Merck; MSD; Nichiiko; Novartis; Ono Pharmaceutical; Pfizer; Sandoz; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health AMEA; Janssen; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Amgen BioPharama (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/UCB Japan (Inst); EP Croit Co. (Inst); EPS Holdings (Inst); Genomic Health (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Preferred Network (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Cancer Net Japan; JAMT
 
Junichi Shimizu
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Merck; MSD Oncology; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Eisaku Miyauchi
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kyorin; Kyowa Kirin; Kyowa Kirin Co Ltd; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Boehringer Ingelheim; Daiichi Sankyo KK; Merck; Ono Pharmaceutical
 
Hiroshige Yoshioka
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Delta-Fly Pharma; Lilly; Merck; MSD K.K; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Delta-Fly Pharma
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Delta-Fly Pharma (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst)
 
Ichiro Yoshino
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo; Intuitive Surgical; Johnson and Johnson; Shionogi; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Medicaroid
Research Funding - Chugai Pharma (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Toshihiro Misumi
Honoraria - Chugai Pharma; Miyarisan pharmaceutical
 
Takashi Kijima
No Relationships to Disclose
 
Kenichi Chikamori
Honoraria - AstraZeneca; Chugai Pharma; Lilly Japan; Nippon Kayaku; Ono Yakuhin; Pfizer; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan; Chugai Pharma; MSD; Takeda
 
Hisashi Tanaka
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Ono Pharmaceutical; Pfizer
 
Kazunori Tobino
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim Seiyaku
 
Tatsuro Fukuhara
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Novartis (Inst); Sanofi (Inst); Takeda (Inst)
 
Hirotaka Kuroki
Employment - Chugai Pharma
Stock and Other Ownership Interests - Chugai Pharma
Travel, Accommodations, Expenses - Chugai Pharma (Inst)
 
Misa Tanaka
Employment - Chugai Pharma
Stock and Other Ownership Interests - Chugai Pharma
Honoraria - Kowa Pharmaceutical (I)
 
Akihiko Gemma
Consulting or Advisory Role - Nihonkayaku
Speakers' Bureau - Daiichi Snkyo